Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus

被引：20

作者：

Xia, Yuan ^{[1
]}

Fang, Xuan ^{[1
]}

Dai, Xiaojuan ^{[1
]}

Li, Manyun ^{[1
]}

Jin, Li ^{[1
]}

Tao, Jinhui ^{[1
]}

Li, Xiaomei ^{[1
]}

Wang, Yiping ^{[2
]}

Li, Xiangpei ^{[1
]}

机构：

[1] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Rheumatol & Immunol, Hefei 230001, Peoples R China

[2] Univ Sydney, Westmead Inst Med Res, Ctr Transplantat & Renal Res, Sydney, NSW, Australia

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2021年 / 96卷

基金：

中国国家自然科学基金;

关键词：

Lupus nephritis; Drug therapy; T-Lymphocytes; Regulatory; Th17; cells; NF-KAPPA-B; T-CELLS; ANTIRHEUMATIC DRUG; DNA ANTIBODIES; KIDNEY INJURY; AGENT T-614; DISEASE; DIFFERENTIATION; ERYTHEMATOSUS; ARTHRITIS;

D O I：

10.1016/j.intimp.2021.107563

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective: Iguratimod, an anti-rheumatic drug, has been widely used in the treatment of rheumatoid arthritis, but is still at an investigative stage for treatment of systemic lupus erythematosus (SLE). We examined the therapeutic effects of iguratimod and the mechanism underlying the efficacy in murine lupus model. Methods: Pristane-induced lupus model of BALB/c mice (PI mice) were treated with iguratimod and mycophenolate mofetil. Proteinuria, anti-dsDNA antibodies and immunoglobulins production were measured. Renal pathology was evaluated. The percentage of Th17 and Treg cells in spleen and the expression of cytokines and mRNAs related to Th17 and Treg cells was analyzed. Results: Iguratimod attenuated the severity of nephritis in PI mice in a dose-dependent manner. Proteinuria was continuously decreased and pathology of glomerulonephritis and tubulonephritis was significantly reduced along with reduction of glomerular immune complex deposition. Also, serum anti-dsDNA and total IgG and IgM levels were reduced by iguratimod in mice. It is worth mentioning that the efficacy of the 30 mg/kg/d iguratimod dose is comparable to, or even better than, 100 mg kg/d of mycophenolate mofetil. Furthermore, the percentage of Th17 cells was found decreased and the percentage of Treg cells increased. ROR-gamma t mRNA and serum cytokines (IL-17A and IL-22) of Th17 cells decreased accordingly. By contrast, Foxp3 mRNA and cytokines (TGF-beta and IL10) of Treg cells increased. Conclusion: Iguratimod ameliorates nephritis of SLE and modulates the Th17/Treg ratio in murine nephritis of SLE, suggesting that Iguratimod could be an effective drug in treatment of SLE.

引用

页数：9

共 35 条

[1] An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with 1κBα degradation [J].